BridgeBio Oncology Therapeutics

BBOT · NASDAQ

$2.72−$0.13 (−4.56%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.85

BBOT analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy10
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $22.33 (+720.8% upside)

Low: $15.15
Now: $2.72
High: $30.45

Upgrades and downgrades

The latest rating actions, newest first

BBOT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Oppenheimer	Oct 20, 2026	Maintains	Outperform	$22.00 → $16.00	17%
JP Morgan	Sep 11, 2026	Maintains	Overweight	$25.00 → $23.00	18%
Leerink Partners	Sep 10, 2026	Maintains	Outperform	$39.00 → $27.00	45%
Canaccord Genuity	Sep 9, 2026	Maintains	Buy	$23.00 → $20.00	35%
Raymond James	Sep 9, 2026	Maintains	Outperform	$24.00 → $22.00	20%
Stifel	Sep 9, 2026	Maintains	Buy	$23.00 → $15.00	39%
Wedbush	Sep 9, 2026	Maintains	Outperform	$25.00	46%
JP Morgan	Aug 14, 2026	Maintains	Overweight	$27.00 → $25.00	18%
JP Morgan	Jul 8, 2026	Initiates	Overweight	$27.00	18%
Oppenheimer	Jun 22, 2026	Initiates	Outperform	$22.00	17%

The case for and against

Updated Oct 16, 2026

Bull case

BridgeBio Oncology is attractive because BBO-8520 is showing strong clinical differentiation, with 63% ORR and 100% DCR in G12C-naive patients, 75% of eligible patients still on treatment beyond 6 months, and no grade 3 liver enzyme elevations. Its pivot toward BBO-8520 plus pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC is strategically sound, targeting a less crowded setting with favorable efficacy versus current standards and peers while preserving the upside of a faster path to market. Beyond that, the company’s broader RAS pipeline adds meaningful optionality: BBO-11818 and BBO-10203 combinations are advancing in CRC and PDAC, supported by a highly synergistic platform with modeled total worldwide peak sales of about $7.5 billion.

Bear case

BridgeBio Oncology is facing a negative fundamental setup because its pipeline remains early-stage, with BBO-8520, BBO-10203, and BBO-11818 all still in Phase 1 and dependent on unproven therapeutic windows, tolerability, and clinical activity. The company’s recent narrowing away from breast cancer and other legacy indications signals internal prioritization and has likely reduced investor confidence, while the crowded KRAS market raises the risk of weaker eventual market share versus better-positioned competitors. Although early safety data are encouraging, any need for large randomized Phase 3 trials would require significant capital and likely equity issuance, creating dilution risk in a business that still has no approved products or meaningful revenue.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.